FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL 3235-0287 Estimated average burden hours per response: 0.5

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

										1					
Name and Address of Reporting Person*     Tanimoto Sarina			2. Issuer Name and Ticker or Trading Symbol ARS Pharmaceuticals, Inc. [ SPRY ]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director  Officer (give title below)  CHIEF MEDICAL OFFICER					
(Last) (First) (Middle) C/O ARS PHARMACEUTICALS, INC. 11682 EL CAMINO REAL, SUITE 120			3. Date of Earliest Transaction (Month/Day/Year) 08/20/2024												
(Street) SAN DIEGO CA 92130		130 p)	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable Line)  Form filed by One Reporting Person  Form filed by More than One Reporting Person					
(City) (S	tive Securities Acquired, Disposed of, or Bene							ficially Owned							
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or			5. Amount of Securities Beneficially Owned Following		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
				Code	v	Amount	(A) or (D)	Price		Reported Transaction(s) (Instr. 3 and 4)	, ,	, ,			
Common Stock										3,407,847	D				
Common Stock		08/20/2024		S		35,944 <sup>(1)</sup>	D	\$14.756	55(2)	1,511,503	I	By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 <sup>(3)</sup>			
Common Stock		08/20/2024		S		11,756 <sup>(1)</sup>	D	\$15.612	29(4)	1,499,747	I	By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 <sup>(3)</sup>			
Common Stock		08/20/2024		S		2,300(1)	D	\$16.258	<b>39</b> (5)	1,497,447	I	By Sarina Tanimoto Charitable Remainder UniTrust Dated January 7, 2020 <sup>(3)</sup>			
Common Stock		08/20/2024		S		36,216 <sup>(1)</sup>	D	\$14.757	76 <sup>(6)</sup>	1,512,283	I	By Lowenthal- Tanimoto Family Trust U/A DTD 4/3/2006 <sup>(7)</sup>			
Common Stock		08/20/2024		S		11,523(1)	D	\$15.623	34(8)	1,500,760	I	By Lowenthal- Tanimoto Family Trust U/A DTD 4/3/2006 <sup>(7)</sup>			

		Table	I - Non-Deriva	tive Securiti	es Acq	uired	l, Dispose	d of, c	or Beneficia	ally Own	ed		
1. Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	action (Instr.	4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amour Securitie Beneficia Owned Following	s F Illy (I Ir g (I	Ownership orm: Direct 0) or direct (I) nstr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	Amount	(A) or (D)	Price	Reported Transacti (Instr. 3 a	ion(s)		
Common	ı Stock		08/20/2024		S		2,261(1)	D	\$16.2532 <sup>(9</sup>	1,498	3,499	I	By Lowenthal- Tanimoto Family Trust U/A DTD 4/3/2006 <sup>(7)</sup>
Common	ı Stock									1,446	5,494	I	By Richard E. Lowenthal Charitable Remainder UniTrust Dated January 7, 2020 <sup>(10)</sup>
Common	Stock									4,315	5,313	I	By Spouse
		Tal	ole II - Derivati (e.g., pu	ve Securities ts, calls, wa							d		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Transaction Code (Instr. 8) Se Ac (A	Number erivative ccurities equired or sposed	Expira	e Exercisable a tion Date h/Day/Year)	A S U D S	Title and mount of ecurities nderlying erivative ecurity (Instr. and 4)	8. Price of Derivative Security (Instr. 5)	9. Number derivative Securities Beneficiall Owned Following Reported	Owner Form: Direct or Indi (I) (Ins	(D) Beneficial Ownership rect (Instr. 4)

## Explanation of Responses:

- 1. The shares were sold pursuant to a Rule 10b5-1 trading plan entered into on March 31, 2023.
- 2. The weighted average sale price for the transaction report was \$14.7565 and the range of prices were between \$14.09 and \$15.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided.

Exercisable

of (D)

(A) (D)

(Instr. 3, 4 and 5)

- 3. The Reporting Person is trustee of the trust.
- 4. The weighted average sale price for the transaction report was \$15.6129 and the range of prices were between \$15.10 and \$16.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided.
- 5. The weighted average sale price for the transaction report was \$16.2589 and the range of prices were between \$16.15 and \$16.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided.
- 6. The weighted average sale price for the transaction report was \$14.7576,and the range of prices were between \$14.09 and \$15.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided.
- 7. The shares are held in trust for the benefit of the Reporting Person and her spouse. The Reporting Person and her spouse are trustees of the trust.

Code

- 8. The weighted average sale price for the transaction report was \$15.6234,and the range of prices were between \$15.10 and \$16.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided.
- 9. The weighted average sale price for the transaction report was \$16.2532 and the range of prices were between \$16.12 and \$16.34. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares old at each separate price will be provided.
- 10. The Reporting Person's spouse is trustee of the trust. The Reporting Person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

/s/ Kathleen Scott, Attorneyin-Fact 08/21/2024

Transaction(s)

(Instr. 4)

\*\* Signature of Reporting Person Date

Amount or Number

Shares

Expiration

Date

Title

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.